Last updated: September 18, 2026
Panobinostat lactate, marketed by Novartis as Farydak, is an oral histone deacetylase inhibitor used with bortezomib and dexamethasone for adults with relapsed multiple myeloma after at least two prior regimens, including bortezomib and an immunomodulatory agent. Its commercial position is constrained by a narrow treatment setting, substantial toxicity-management requirements, and competition from newer multiple-myeloma therapies. Public filings do not provide a current standalone revenue series for Farydak, so its financial trajectory is best assessed through product positioning, market access, competitive displacement, and Novartis portfolio reporting.
What is panobinostat lactate and how is it marketed?
Panobinostat lactate is the lactate salt of panobinostat, a nonselective inhibitor of histone deacetylases. The drug is supplied as oral capsules in 10 mg, 15 mg, and 20 mg strengths. The marketed product is Farydak, developed and commercialized by Novartis.
| Item |
Details |
| Active ingredient |
Panobinostat |
| Salt form |
Panobinostat lactate |
| Brand |
Farydak |
| Company |
Novartis |
| Drug class |
Histone deacetylase inhibitor |
| Route |
Oral |
| Initial U.S. approval |
February 2015 |
| FDA pathway |
Accelerated approval |
| Primary disease |
Relapsed or refractory multiple myeloma |
| Core combination |
Bortezomib plus dexamethasone |
| Initial U.S. population |
Patients with at least two prior regimens, including bortezomib and an immunomodulatory agent |
| Regulatory basis |
PANORAMA-1 progression-free-survival data |
| Key safety issues |
Diarrhea, thrombocytopenia, fatigue, nausea, infection, bleeding, QT prolongation |
The FDA approved Farydak under the accelerated-approval pathway based on improved progression-free survival in the PANORAMA-1 trial. The treatment’s clinical value depends on combination use rather than monotherapy, which limits its addressable market and increases prescribing complexity (U.S. Food and Drug Administration, 2015).
What is the FDA regulatory status of panobinostat lactate?
Farydak remains an FDA-approved treatment for relapsed multiple myeloma. The labeled use is narrower than the broad relapsed-multiple-myeloma market because treatment is tied to prior exposure to bortezomib and an immunomodulatory drug.
The FDA label includes intensive monitoring requirements:
- Complete blood counts before treatment and during therapy.
- Electrolyte monitoring.
- Electrocardiograms for patients at risk of QT prolongation.
- Management of severe diarrhea and dehydration.
- Dose interruptions or reductions for thrombocytopenia, neutropenia, and gastrointestinal toxicity.
- Avoidance or careful management of strong CYP3A inhibitors and inducers.
The drug’s safety profile has commercial consequences. Prescribers may favor agents with simpler administration or more predictable tolerability, particularly when several active therapies are available after prior exposure to proteasome inhibitors and immunomodulatory agents.
How large is the addressable market for Farydak?
The addressable market is a late-line segment of multiple myeloma rather than the full disease population. Farydak is most relevant for patients who have:
- Received at least two previous regimens.
- Previously received bortezomib.
- Previously received an immunomodulatory agent.
- Retained sufficient marrow, cardiac, renal, and gastrointestinal function for treatment.
This positioning reduces volume potential. The product does not compete equally across first-line, maintenance, or early-relapse settings. Its commercial opportunity is concentrated among heavily pretreated patients and centers comfortable managing combination-related toxicities.
The multiple-myeloma market has expanded substantially since Farydak’s approval, but treatment competition has also intensified. Daratumumab, carfilzomib, pomalidomide, selinexor, belantamab mafodotin in relevant markets, bispecific antibodies, and CAR-T therapies compete for later-line patients. Many of these therapies have stronger differentiation through overall-survival data, targeted mechanisms, convenient combination structures, or use in earlier disease settings.
How does panobinostat compare with competing multiple-myeloma drugs?
Farydak’s principal commercial weakness is that its mechanism is differentiated but its treatment experience is comparatively demanding.
| Therapy |
Class |
Typical competitive advantage |
Commercial pressure on Farydak |
| Panobinostat |
HDAC inhibitor |
Oral administration; activity after multiple prior therapies |
Gastrointestinal and hematologic toxicity |
| Carfilzomib |
Proteasome inhibitor |
Established efficacy in relapsed disease |
Intravenous administration and cardiovascular risk |
| Pomalidomide |
Immunomodulatory agent |
Oral dosing and established combination use |
Overlapping heavily pretreated population |
| Daratumumab |
Anti-CD38 antibody |
Broad use across treatment lines; strong clinical adoption |
Displaces later-line combination regimens |
| Selinexor |
XPO1 inhibitor |
Oral option for heavily pretreated disease |
Competes for treatment-refractory patients |
| Bispecific antibodies |
Immune engager |
High response rates in later-line disease |
Rapidly changes treatment sequencing |
| CAR-T therapies |
Cell therapy |
Deep responses in eligible patients |
Removes some high-value late-line patients from chronic therapy |
Panobinostat has a place where physicians value an oral, non-immunomodulatory mechanism after multiple prior therapies. Its role is weaker where treatment selection is driven by rapid response, long-term disease control, or lower gastrointestinal toxicity.
What is the financial trajectory of panobinostat lactate?
Novartis does not consistently report Farydak as a separately quantified revenue line in recent public financial disclosures. The product is grouped within broader portfolio categories or is omitted from detailed product-level sales tables once its contribution becomes immaterial to consolidated results. A precise current revenue estimate cannot therefore be derived from Novartis annual reports alone.
The financial trajectory can be divided into four phases:
| Phase |
Commercial condition |
Financial implication |
| 2015 launch |
Introduction into a defined relapsed-myeloma population |
Initial revenue generation from accelerated approval |
| Early commercialization |
Specialist adoption and use after bortezomib and immunomodulatory therapy |
Moderate niche-product potential |
| Competitive erosion |
Expansion of daratumumab, carfilzomib, pomalidomide, selinexor, and cellular therapies |
Reduced treatment share and lower growth potential |
| Mature lifecycle |
Limited-line indication, generic scrutiny, and reduced company disclosure |
Likely declining or immaterial standalone contribution |
Novartis’s financial reporting structure is important. Once a product becomes small relative to the company’s major growth brands, public reporting normally shifts away from standalone product revenue. That does not establish zero sales. It indicates that Farydak is no longer financially material enough to receive consistent product-level disclosure.
The product’s revenue ceiling was constrained from launch by its treatment line, combination requirement, and tolerability. It did not have the commercial architecture of a broad chronic therapy or a first-line oncology product.
When does panobinostat lactate lose exclusivity?
Panobinostat is a small molecule, so the relevant post-exclusivity risk is generic competition rather than biosimilar competition. The timing depends on the specific patent, regulatory exclusivity, jurisdiction, pediatric extensions, and the scope of any generic applicant’s Paragraph IV challenge.
The original composition-of-matter and salt-related patent estate has been central to U.S. exclusivity analysis. Public Orange Book records should be used for the current listed patents, expiration dates, and use codes because listed patents can change through corrections, delistings, pediatric extensions, and litigation outcomes.
A commercial exclusivity assessment should distinguish among:
- Chemical compound patents.
- Panobinostat lactate salt patents.
- Crystal-form or polymorph patents.
- Pharmaceutical-composition patents.
- Method-of-treatment patents.
- Manufacturing and process patents.
- Regulatory exclusivity independent of patent protection.
The existence of a later-expiring method or formulation patent does not necessarily prevent all generic entry. A generic applicant may pursue a Paragraph IV certification, label out protected uses, or challenge the validity or enforceability of listed claims.
What is the Orange Book and Paragraph IV risk for Farydak?
The Orange Book is the primary U.S. source for FDA-listed patents and exclusivity associated with approved drug products. For Farydak, the commercial significance of any listed patent depends on whether the patent covers the active ingredient, the marketed salt, the dosage form, or only a specific use.
A generic applicant filing an abbreviated new drug application may certify that a listed patent is invalid, unenforceable, or will not be infringed. That Paragraph IV certification can trigger patent litigation if the innovator files suit within the statutory period. The litigation can create a 30-month stay of FDA approval, subject to statutory exceptions and court developments.
The main generic-entry scenarios are:
| Scenario |
Effect on Farydak |
| No generic filing |
Continued niche sales until commercial or patent erosion |
| Paragraph IV challenge defeated |
Innovator protection continues for the relevant patent term |
| Paragraph IV settlement |
Entry date depends on settlement terms |
| Label carve-out |
Generic may enter for unprotected indications or uses |
| Invalidity or non-infringement ruling |
Earlier generic entry risk |
| At-risk launch |
Potential immediate price and share erosion, followed by damages exposure |
No public information in the available record establishes a major generic launch or a definitive settlement that has already transformed the Farydak market. Any investment model should therefore separate confirmed regulatory events from assumed entry dates.
Are biosimilars a risk to panobinostat lactate?
No. Biosimilar competition does not apply directly because panobinostat lactate is a chemically synthesized small molecule, not a biologic. The relevant threats are:
- ANDA-based generic entry.
- Authorized generic competition.
- Patent expiration.
- Therapeutic substitution by newer multiple-myeloma products.
- Formulary restrictions.
- Clinical displacement in treatment sequencing.
This distinction matters because generic entry can occur through the Hatch-Waxman pathway, while biosimilar competition follows the Biologics Price Competition and Innovation Act.
What formulation and manufacturing protections matter?
The oral capsule formulation is commercially important because it provides outpatient administration, but it also creates a potential generic-development pathway. Relevant intellectual-property questions include:
- Whether claims cover the lactate salt specifically.
- Whether the claimed composition requires particular excipients.
- Whether capsule strength or dissolution characteristics are protected.
- Whether generic manufacturers can use a non-infringing salt or formulation.
- Whether process claims create a practical manufacturing barrier.
- Whether the approved-label indication can be carved out.
Manufacturing is unlikely to create a durable barrier comparable to complex biologics manufacturing. Panobinostat is a small molecule, and generic manufacturers generally have more feasible options for developing chemically equivalent products. Process patents can delay or complicate entry, but they rarely provide the same structural protection as a broad composition-of-matter patent.
What licensing deals affect panobinostat lactate?
Farydak is principally associated with Novartis. The public commercial narrative is not based on a major external licensing transaction comparable to products acquired through large biotechnology deals. The central value drivers are Novartis ownership, the Farydak brand, the drug’s approved combination with bortezomib and dexamethasone, and the company’s ability to maintain reimbursement in a competitive hematology market.
Because Farydak is a mature, niche asset, any future transaction would more likely involve regional commercialization rights, portfolio rationalization, or a specialty-pharma acquisition than a large strategic licensing deal.
What patent litigation affects panobinostat lactate?
The most important litigation risk is generic patent litigation under the Hatch-Waxman framework. The economic outcome depends on the claims asserted and whether they cover the active salt, formulation, or method of treatment.
A complete current litigation assessment requires live review of:
- FDA Orange Book listings.
- ANDA Paragraph IV notices.
- U.S. district-court complaints.
- Federal Circuit appeals.
- Patent Trial and Appeal Board proceedings.
- Settlement agreements.
- FDA approval dates for abbreviated applications.
A confirmed generic launch, settlement, or invalidity ruling could materially alter the product’s residual value. In the absence of such an event, therapeutic competition remains the more immediate pressure on demand.
What is the geographic coverage of panobinostat lactate?
Farydak received regulatory approval in the United States and was commercialized in other major markets, including Europe, subject to local authorization and reimbursement decisions. Geographic revenue is likely concentrated in the United States, major European markets, and Japan, where multiple-myeloma treatment infrastructure and specialty-drug reimbursement support use.
Market access varies by country. Key restrictions include:
- Prior authorization.
- Requirement for prior bortezomib and immunomodulatory therapy.
- Specialist prescribing.
- Combination-treatment reimbursement.
- National assessment of progression-free-survival benefit.
- Cost-effectiveness review.
- Availability of alternative late-line treatments.
A product with a narrow label can retain clinical use while losing reimbursement breadth as newer therapies enter preferred pathways.
How strong is the panobinostat lactate commercial position?
The patent position is more valuable as a delaying asset than as a long-term growth platform. The commercial position is moderate to weak because:
- The label targets a late-line population.
- Treatment requires combination administration.
- Toxicity management is substantial.
- Multiple competing regimens are available.
- Newer immune-based therapies compete for the same patients.
- Novartis no longer highlights the product as a major growth driver.
- Small-molecule generic entry remains feasible after relevant protections expire.
Farydak may retain residual value in selected relapsed-myeloma patients, particularly where oral administration or prior treatment history favors its use. Its strategic value is limited compared with Novartis’s major growth products and newer hematology assets.
Key Takeaways
- Panobinostat lactate is marketed as Farydak by Novartis.
- The FDA-approved use is a narrow, late-line multiple-myeloma indication.
- The drug’s main commercial liabilities are gastrointestinal and hematologic toxicity, combination dependence, and intense competition.
- Public Novartis disclosures do not provide a consistent current standalone revenue figure for Farydak.
- Farydak faces generic risk under the Hatch-Waxman framework, not biosimilar risk.
- Orange Book patent scope and any Paragraph IV activity are the decisive U.S. exclusivity variables.
- Therapeutic displacement is likely more important than revenue expansion.
- Manufacturing barriers are lower than for biologic products because panobinostat is a small molecule.
- The asset has residual specialty-market value but limited prospects as a material growth product.
FAQs About Panobinostat Lactate
Is panobinostat lactate the same drug as Farydak?
Yes. Farydak is the branded product containing panobinostat, supplied as the lactate salt.
Is panobinostat lactate still used for newly diagnosed multiple myeloma?
No. Its FDA-approved role is in relapsed or refractory multiple myeloma after specified prior therapies. It is not a standard first-line treatment.
Does panobinostat lactate have biosimilar competition?
No. It is a small-molecule drug. Competition would occur through generic-drug applications rather than biosimilar applications.
Why has Farydak not become a leading multiple-myeloma product?
Its use is limited by late-line positioning, required combination therapy, gastrointestinal and hematologic toxicity, and competition from antibodies, proteasome inhibitors, immunomodulatory agents, bispecific antibodies, and CAR-T therapies.
What is the main investment risk for panobinostat lactate?
The main risk is declining utilization from therapeutic substitution and eventual generic entry, combined with the absence of a broad indication or material standalone revenue disclosure.
References
-
Novartis AG. (2015). Annual report 2015. Novartis. https://www.novartis.com/investors/financial-data/annual-reporting
-
Novartis AG. (2023). Annual report 2023. Novartis. https://www.novartis.com/investors/financial-data/annual-reporting
-
U.S. Food and Drug Administration. (2015). FDA approves Farydak for multiple myeloma. https://www.fda.gov
-
U.S. Food and Drug Administration. (2024). Farydak (panobinostat) prescribing information. Novartis Pharmaceuticals Corporation. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
National Cancer Institute. (2024). Panobinostat. NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/panobinostat
